Patent ID: 8497246

Claim:
A method of treating a CNS disorder comprising systemically administering to an individual suffering from the disorder an effective amount of a composition comprising a first and second antibody, wherein: a. the first antibody is an ScFv antibody that is covalently linked to the carboxy terminus of the second antibody; b. the second antibody comprises an Fc region capable of crossing the BBB from the brain to the blood; and either i) the first antibody is capable of crossing the Blood-Brain Barrier (BBB) from the blood to the brain by binding a receptor BBB transport system and the second antibody is capable of interacting with a pathological substance associated with the disorder; or ii) the second antibody is capable of crossing the Blood-Brain Barrier (BBB) from the blood to the brain by binding a receptor BBB transport system and the first antibody is capable of interacting with a pathological substance associated with the disorder, wherein the ScFv retains at least 10% of its affinity compared to the affinity of the tetrameric immunoglobulin from which ScFv can be derived.